Russ Conroy

Findings from a secondary analysis of a phase 3 trial support stereotactic radiosurgery as a standard of care for those with brain metastases, although whole-brain radiotherapy may yield more local and distant control.

Findings from a randomized trial highlight that treatment with mirtazapine may lead to an improvement in health-related quality of life among those with advanced non–small cell lung cancer and anorexia.

Adding adaptive radiation to chemotherapy may offer a novel approach to treating patients with advanced non–small cell lung cancer, according to Michael Steinberg, MD.

Treatment with imetelstat produces robust activity in patients with relapsed/refractory myelodysplastic syndrome regardless of ring sideroblasts in the phase 3 IMerge trial.

Adding pegylated L-asparaginase to consolidation chemotherapy demonstrates a modest decrease in minimal residual disease negativity among those with high-risk acute lymphoblastic leukemia.

Findings from the phase 2 JACKPOT8 study support golidocitinib as a potential treatment option for those with relapsed or refractory peripheral T-cell lymphoma.

Findings from the phase 3 KEYNOTE-A18 trial support the FDA approval of pembrolizumab plus external beam radiotherapy and concurrent chemotherapy in stage III to IVA cervical cancer.

The FDA has set a Prescription Drug User Fee Act date of June 29, 2024 for SH-105 as a treatment for patients with ovarian cancer or breast cancer.

Investigators are assessing the safety and antitumor activity of rinatabart sesutecan in advanced epithelial ovarian cancer as part of the phase 1/2 PRO1184-001 study.

Findings from a retrospective study highlight an increase in the use of targeted agents like ibrutinib from 1998 to 2020 for American military veterans with chronic lymphocytic leukemia.

Investigators report high response rates with pirtobrutinib in those with mantle cell lymphoma and high-risk disease features in the phase 1/2 BRUIN trial.

The FDA cannot approve the application for zolbetuximab in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma due to unresolved issues following a pre-license inspection of a third-party manufacturing site.

The FDA has set a Prescription Drug User Fee Act date of May 9, 2024 for the potential full approval of tisotumab vedotin for those with recurrent or metastatic cervical cancer.

Treatment with asciminib produces a favorable safety profile among patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Treatment with iopofosine I 131 appears to be well tolerated among patients with relapsed/refractory Waldenström macroglobulinemia.

Treatment with atezolizumab monotherapy yields an acceptable toxicity profile compared with chemotherapy among those with advanced or metastatic urothelial carcinoma.

A population of patients with multiple myeloma describes experiencing challenges including confusion regarding the complexities of their diagnoses and managing chronic treatment-related adverse effects in a qualitative study.

It is crucial to ensure equitable access to high-quality survivorship care among lesbian, gay, and bisexual adolescent and young adult cancer survivors, according to Michael E. Roth, MD.

The FDA lifts its hold on a clinical program for lacutamab in lymphoma after a fatal adverse effect in the phase 2 TELLOMAK trial is determined to be related to aggressive disease progression.

Findings from a phase 3 trial highlight regression of central nervous system metastases across all heavily pretreated breast cancer subtypes with Bria-IMT.

Data from a phase 2 trial support the potential survival benefit of CAN-2409 plus prodrug for patients with borderline resectable pancreatic ductal adenocarcinoma.

Patients with non–small cell lung cancer who already received LN-145 in the phase 2 IOV-LUN-202 trial will be followed per trial protocol following the FDA’s clinical hold.

A review from the FDA confirms the dose comparison post-marketing requirement that was detailed at the time of sotorasib’s accelerated approval for those with KRAS G12C–mutated non–small cell lung cancer.

A panel of experts spoke about the armamentarium of bispecific antibody therapies for patients with relapsed/refractory multiple myeloma and discussed step-up dosing considerations for these approved agents.

Oncoplastic surgery requires collaboration between different surgical teams, pathologists, and radiologists to ensure optimal cosmetic and survival outcomes for patients with breast cancer, says Roshani Patel, MD, FACS.

Data from a meta-analysis may provide safety insights for future randomized clinical trials evaluating immune checkpoint blockade in the definitive setting for patients with cancer.

Investigators will assess the safety and preliminary clinical activity of MRBC-101 in patients with EphA5-expressing malignant solid tumors as part of a phase 1/1b trial.

Those with chronic graft-versus-host-disease who have received allogeneic hematopoietic stem cell transplant may experience enhanced graft-versus-leukemia effects, thus producing a lower relapse rate in acute myeloid leukemia.

The efficacy of HIPEC plus cytoreductive surgery appears to be consistent across ovarian cancer subgroups based on age, histological type, and pre-surgery laparoscopy in the phase 3 OVHIPEC-1 trial.

Data from a real-world study may help clinicians in treatment decision-making for those with extensive-stage small cell lung cancer who are unable to afford PD-L1 inhibitors.